Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Tesaro, Inc.
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian Cancer
In order to request this CME/CE activity for your center, please contact Samantha Zelasko at SZelasko@gotoper.com or call (609) 325-4668
Oncology Best Practice™:
Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian Cancer
Clinical research continues to develop new and novel treatment options that can improve outcomes for your patients with ovarian cancer. Agents that target the PARP (poly[ADP-ribose] polymerase) family of proteins are in various stages of development and approval. PARP plays an important role in numerous cellular functions, including DNA transcription, DNA repair, cell cycle regulation, cell signaling, and cell death. The targeted inhibition of PARP in BRCA-mutated or “BRCA-like” tumor cells can prevent DNA repair, induce synthetic lethality, and lead to tumor cell death.
Several PARP inhibitors have demonstrated efficacy in the treatment of patients with ovarian cancer in multiple clinical trials. With three FDA-approved agents, and several others in late clinical development, this class of medications has become a new standard of care.
Community oncologists treat the vast majority of patients with ovarian cancer. Understanding and implementing clinical trial results into the community practice setting is an essential aspect of providing care for your patients.
This program will bring experts in the management of ovarian cancer directly to your institution for an in-depth discussion on how to optimize treatment with you and your team. Practical scenarios, case-based approaches, and dynamic interactions keep one thing in focus: the patient. From integrating clinical data, to updated sequencing strategies, and adverse event management, this traveling tumor board will cover all things PARP.
This activity is directed toward medical, surgical and radiation oncologists who treat or manage patients with ovarian cancer. Fellows, nurses, nurse practitioners, physician assistants, researchers, pharmacists and other healthcare professionals interested in the treatment or management of these tumors are also invited to participate.
At the conclusion of this activity, you should be better prepared to:
- Describe how PARP inhibition strategies have been applied to the management of recurrent ovarian cancer
- Discuss how care can be personalized via the use of testing strategies in BRCA-mutant and non-BRCA-mutant patient populations with ovarian cancer
- Examine the current emerging roles of PARP inhibitors in maintenance therapy for ovarian cancer
- Describe effective strategies to proactively plan for and manage treatment-related toxicities in the setting of ovarian cancer
Michael Birrer, MD, PhD
Director, University of Alabama, Birmingham
Comprehensive Cancer Center
Professor of Medicine
Division of Hematology & Oncology